In vivo metabolism of apolipoprotein E within the HDL subpopulations LpE, LpEA-I, LpEA-II and LpEA-IA-II》.pdfVIP

Atherosclerosis 165 (2002) 205 /220 /locate/atherosclerosis In vivo metabolism of apolipoprotein E within the HDL subpopulations LpE, LpE:A-I, LpE:A-II and LpE:A-I:A-II Minna L. Hannuksela a,b,*, Margaret E. Brousseau a, Susan M. Meyn a, Hassan Nazih a, Giovanni Bader a, Robert D. Shamburek a, Petar Alaupovic c, H. Bryan Brewer, Jr. a a Molecular Disease Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA b Department of Internal Medicine and Biocenter Oulu, University of Oulu, Kajaanintie 50, 90220 Oulu, Finland c Lipid and Lipoprotein Laboratory, Oklahoma City, OK, USA Received 30 May 2001; received in revised form 23 April 2002; accepted 28 May 2002 Abstract High-density lipoproteins can be separated into distinct particles based on their apolipoprotein content. In the present study, the in vivo metabolism of apoE within the apoE-containing HDL particles LpE, LpE:A-I, LpE:A-II and LpE:A-I:A-II was assessed in control subjects and in patients with abetalipoproteinemia (ABL), in whom HDL are the sole plasma lipoproteins. The metabolism of apoE within these HDL subspecies was investigated in three separate studies which differed by donor or recipient status: (1) particles purified from normolipidemic plasma and reassociated with 125I or 131I-labeled apoE injected into normolipidemic subjects (study 1); (2) particles purified from ABL plasma injected into normolipidemic subjects (study 2); and (3) particles purified from ABL plasma injected into ABL s